Navigation Links
Immune Design Appoints Stephen R. Brady Chief Business Officer
Date:9/26/2013

SEATTLE and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Stephen R. Brady as its Chief Business Officer.

(Logo: http://photos.prnewswire.com/prnh/20130926/SF87058LOGO)

Mr. Brady brings extensive experience to lead Immune Design's business functions, including strategic planning and corporate development activities. His appointment in this new position is a reflection of the Company's maturing immune-based therapeutic programs and productive platform technology.

"Steve is an experienced and accomplished executive with a successful track record of executing successful business development and corporate strategies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "He is a key addition to our expanded management team and will play an important role in advancing and expanding our strategic activities."

"Immune Design's combination of both novel antigen-specific and innate immunity approaches is an exciting potential advancement in the area of cancer immunotherapy," said Mr. Brady.  "I look forward to working with the team to move existing programs forward and further expand the reach of the company's platform technology in oncology, infectious disease and allergies."

Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal a
'/>"/>

SOURCE Immune Design
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
2. NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
3. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
6. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
7. Penn researchers develop protein passport that help nanoparticles get past immune system
8. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
9. Small peptide ameliorates autoimmune skin blistering disease in mice
10. New Research Helps Explain Weakened Immune Response in Elderly
11. Autoimmune disease retraining white blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... ), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking ... , , Date:  May ... Time:  8:30am Pacific Time , , , ... , , ...
... HONG KONG , May 10 /PRNewswire-FirstCall/ ... Cypress Biosciences ("Cypress"), its development partner for Indaflex, that ... the termination of all Indaflex activity in the ... Chinese market. AlphaRx is working diligently with its regulatory ...
... NEW YORK , May 10 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical,company dedicated to improving health through the development, manufacture and,commercialization of a broad ... the first quarter ended March,31, 2010 . , ... First Quarter 2010 Financial Performance , ...
Cached Biology Technology:Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 3American Oriental Bioengineering Reports First Quarter 2010 Financial Results 4American Oriental Bioengineering Reports First Quarter 2010 Financial Results 5American Oriental Bioengineering Reports First Quarter 2010 Financial Results 6American Oriental Bioengineering Reports First Quarter 2010 Financial Results 7American Oriental Bioengineering Reports First Quarter 2010 Financial Results 8
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... next five years for a pilot project to assess ... conditions can and should become a routine part of ... launched today by the National Institutes of Health to ... as part of, or instead of, the current newborn screening ...
... September 5, 2013, Shenzhen, China BGI in collaboration ... other Chinese institutes, have completed the genome sequencing of ... infectious disease tuberculosis (TB). The study published online in ... researchers to better understand the genetic basis underlying drug ...
... known for some time that the blood vessels that transport ... are more than just bodily pipelines. Arterioles and capillaries, the ... flow of the blood they,re carrying. Biomedical engineers at Drexel ... that explains just how they do it. The team, ...
Cached Biology News:UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
ANTI PIG LDH H4...
... ideal for use in refrigerators, freezers, or liquid nitrogen. ... colors allow for color coding to project, user, lab, ... or promote cool air circulation. Supplied with 10 x ... Box dimensions: 13 x 13 x 5.1 ...
Biology Products: